Latest news with #GaryCook
Daily Mail
06-05-2025
- Daily Mail
EXCLUSIVE The migrant hotel that has turned a quiet country idyll upside down. Locals complaine loitering asylum seekers ask for cash and even peer through our windows
Locals are pleading for a migrant hotel on a quiet country road to be shut down because its residents are making their lives a misery. The Sandpiper Hotel, just outside historic Chesterfield in rural Derbyshire, has been used to accommodate asylum seekers for around two years. But residents claim antisocial behaviour by the residents is now getting out of hand, complaining of noise, litter and groups of men 'loitering', asking for money and looking through people's windows. One said there had been a slump in local house prices. The hotel, which has 46 bedrooms, was previously a three-star Best Western popular with visitors to the Peak District before it closed down. The site was then reopened under a Home Office contract to house asylum seekers, though locals claimed they were 'not consulted'. In December 2023, a 27-year-old man living at the hotel was arrested on suspicion of possessing explosives, although he was later released on bail pending inquiries - with officers saying nothing found at the site posed any danger to the public. Today, locals living on an otherwise quiet and peaceful street near the hotel complained of the disruption it was causing to their lives. Shannon Freeman, 31, said: 'We see the comings and goings. 'They have been on the street looking through people's windows. We got cameras and that seemed to stop. 'The police were there just a couple of minutes ago. 'I have been here since this street was built three years ago and the asylum seekers have been here for two years. 'They were fine at first. It is only in the last six months they have started to behave in a bad way. 'We have been warned on Facebook not to walk on the trail behind the Sandpiper because of talk of men following women through the park. 'We don't know their history or where they come from and the walk backs directly onto the hotel.' Gary Cook's family used to own the hotel but it changed hands a number of times before the contract with the Home Office. Mr Cook, who lives nearby, said: 'I think there are about 80 blokes in there and it has lowered the value of the houses around here and it is not great for the hotel. 'I think it is totally run down now. So it will be hard to get over the stigma and turn it back into a hotel. 'It is not an ideal scenario. It is a shame to see it laid to waste. I do blame profiteering by the hotel groups.' Chelsea Lodge, a 23-year-old mother of two, declared: 'I have come off the bus three times and they have been running up asking for money. 'So, I would rather just get rid of them to be honest. I don't know why they have put them here. I know most of them are all right but there are a few that are not sensible to be around. 'It is not right that they are there and the homeless do not get anything. It is not an ideal hotel for them anyway. 'I have been walking in the woods at the back with my partner and we have had two guys walking behind us. We wondered what are they doing. 'There are a lot of kids around here. They are building a kiddie's play park too. It is just not the right area for asylum seekers.' Mother-of-one Marina Tamasauskas, 41, whose grandfather was from Lithuania, said: 'I am not racist but they are causing problems. 'They have been loitering on the streets. One of the blokes was filming out the windows. 'My girl is in Year Six and and normally walks home alone from school. 'But I had to walk up and get her a couple of months ago when we heard some men were hanging around.' Caroline Winn, a 38-year-old mother of four, said: 'It needs to stop. It used to be a beautiful hotel. 'We see groups of them walking up the road in the middle of the night with bats and golf clubs. They are not going to play golf are they? 'I cannot let my 14-year-old daughter walk my dog any more up and down the trail. Two girls got accosted, filmed, and harassed by them. 'There is no problem with people who come here and want to work and contribute. It is just sad that my daughter cannot walk her dog any more.' Rosie Furniss, 29, added: 'It is not ideal. I have a four month old boy and dare not take him for a walk with the dog because I have heard of them following young girls. 'The bomb squad were there not long ago. The hotel was meant to be accommodating women and children here but it is only younger men. 'I dare not leave my house sometimes on my own. It is good I have a big dog but I don't feel safe. We are actually considering moving because of this. 'The things I have heard about what is going on there make me feel we just have to move. It is a shame. But I just cannot see another way. 'If you complain you get called racist. But how they are acting has got nothing to do with race.' Residents living directly opposite the hotel were keen to give their opinions but not their names because of fear of being targeted. One woman said: 'They're just messy. They throw things on the floor and don't pick them up and put their washing on the shrubbery across the road. I just wish it was not happening. 'I take no notice of them most of the time but they are not very friendly. I was trying to get off the bus with a lot of shopping and had to squeeze past six of them getting on.' A male pensioner added: 'They are getting everything for nothing and don't know how to behave. When they have a drink of coffee they just chuck the cup away. They cannot be made to tidy up. 'You cannot go in to complain because when you get to the door someone from the Home Office comes out and tells us they can do what they like. 'There used to be a number so you could ring up the hotel but that has gone. It is getting out of hand and all we can do is complain to one another. 'I have never voted Tory but I would not not vote for Labour now to save my life. The local elections will show them which way the wind is blowing.' Another woman said: 'They keep themselves to themselves. But no one was consulted about them moving in. They just appeared. 'We had no idea. It was a derelict hotel they took over. The worst thing is they chuck litter everywhere or are sitting around smoking weed. 'If they come here for asylum they should at least put their rubbish in the bin. I have a sixteen year old daughter and don't feel she can walk on the trail behind the hotel because there are so many of them walking around in groups. 'We don't know their history. If you go off the beaten track you do not know if you are being followed. 'My daughter likes to go for a run but she cannot go where she wants because as a female she does not feel safe.' Police were called to reports of a man acting suspiciously at the Sandpiper Hotel in on December 21. A 27-year-old man was arrested at the scene on suspicion of possessing explosives under suspicious circumstances, contrary to Section 4 of the Explosive Substances Act 1883. Officers confirmed at the time nothing at the hotel was found to pose any danger to the public and the man was released on police bail while inquiries continue.
Yahoo
12-02-2025
- Business
- Yahoo
Illuccix® Approved in the United Kingdom
MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the Marketing Authorization Application (MAA) for its prostate cancer PET1 imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection). Illuccix is indicated in the UK for the detection and localization of prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET. PSMA-PET imaging2 represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT3 scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). Global guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease and evaluation of BCR/biochemical persistence (BCP)4. Gary Cook, MD, Professor of Molecular Imaging at Kings College London School of Biomedical Engineering & Imaging Sciences, commented, 'PSMA-PET supply shortages in the UK and Europe have escalated over the past 12 months as demand increases, which has led to delays for men in urgent need of a scan to direct clinical management. It is great news that Telix can now help address this unmet need and improve equity of access in the UK through their Illuccix imaging agent and network distribution model.' Raphaël Ortiz, Chief Executive Officer, Telix International added, 'PSMA-PET imaging is one of the most important developments in prostate cancer detection in recent years and we are delighted that we can now bring Illuccix to physicians and their patients across the UK. A key advantage of Illuccix is that the radioisotope (gallium-68) can be produced using a generator locally, taking just a few minutes with minimal equipment. Reliable service delivery combined with greater scheduling flexibility, including in non-metropolitan locations, will benefit patients, physicians and clinical sites in the UK.' Illuccix will be made available in the UK through Telix's exclusive distribution partner, Xiel Limited, a specialist distributor of nuclear medicine, radiotherapy and diagnostic radiology technologies across the UK and Ireland. To order or enquire about Illuccix availability, UK healthcare professionals can email: radiopharm@ or call +44 (0)1749 372217. About Illuccix® Telix's prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)5, by the Australian Therapeutic Goods Administration (TGA)6, by Health Canada7, by the Danish Medicines Agency8, and by the UK MHRA. Illuccix is currently in national approval review in 19 European countries following a positive decentralized procedure (DCP) opinion by BfArM9. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX). Telix's osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix's miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as 'may', 'expect', 'intend', 'plan', 'estimate', 'anticipate', 'believe', 'outlook', 'forecast' and 'guidance', or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. _______________1 Positron emission tomography.2 Imaging of prostate-specific membrane antigen with positron emission tomography.3 Computed tomography.4 EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3.: Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2023: Telix ASX disclosure 20 December 2021.6 Telix ASX disclosure 2 November 2021.7 Telix ASX disclosure 14 October 2022.8 Telix media release 11 February 2025.9 The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte). Telix ASX disclosure 17 January in to access your portfolio
